Our results indicate that the levels of peripheral blood Tr1 and CD4 + IL10 + cells are increased in patients with T2DM, at different stages of the disease, and that GLP-1-RA therapy might revert this immune dysregulation. The gene discussed is IL10; the disease is rheumatoid arthritis.